Phase II trial of oral carmofur in advanced pancreatic carcinoma

Thirty-one patients with advanced carcinoma of the pancreas and with no prior exposure to chemotherapy were treated with HCFU. This drug was administered orally at a dose of 300-500 mg/m2 in 6-week cycles with a 2-week interval between the cycles. One partial response was observed and 7 patients showed stable disease. The median survival of the 31 patients was 8.3 +/- 5.4 months (range 1.3-20.3 months). The toxicity was moderate.